Super Selective Adrenal Artery Embolization for Primary Aldosteronism: a Prospective Cohort Study(SAAE-PA)

Launched by XINJIANG MEDICAL UNIVERSITY · Jul 15, 2024

Keywords

ClinConnect Summary

The clinical trial titled "Super Selective Adrenal Artery Embolization for Primary Aldosteronism" is exploring a new treatment method for a condition called primary aldosteronism, which is related to an imbalance of hormones that can lead to high blood pressure. This study aims to assess how effective and safe a procedure called adrenal artery embolization is, which involves blocking certain blood vessels to reduce hormone production in the adrenal glands. By understanding this treatment better, the researchers hope to improve diagnosis and care for patients with primary aldosteronism.

To participate in this study, you need to be between 18 and 60 years old and have been diagnosed with primary aldosteronism based on specific medical guidelines. Participants should be willing to try adrenal artery embolization if they have had issues with medications or surgery due to side effects or other risks. Throughout the trial, participants can expect close monitoring and care while receiving this new treatment option. It's important to note that certain health conditions, like severe liver disease or recent heart issues, may prevent someone from joining the study. If you're interested in learning more, discussing with your doctor can help you understand if this trial could be right for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-60 years old;
• • Primary hyperaldosteronism was diagnosed in strict accordance with the 2016 International Endocrine Society clinical guidelines;
• • Refusal of medication due to adverse reactions, refusal of adrenal resection due to surgical risk, or persistent hyperaldosteronism and cortical insufficiency after adrenal resection;
• • The patients and their families were introduced in detail to all the current treatment methods for primary aldosteronism, and the adrenal artery embolization was voluntarily accepted;
• Exclusion Criteria:
• • A history of severe hypersensitivity to contrast media;
• • There are serious complications of liver disease, such as thrombocytopenia, esophageal variceal bleeding, etc;
• • Renal insufficiency (serum creatinine \> 176mmol/L or estimated glomerular filtration rate \< min.1.73m2);
• • Combined with other secondary hypertension, such as pheochromocytoma, hypercortisolism, renal vascular hypertension (such as renal artery stenosis), renin secretory tumor, renal parenchymatous hypertension, drug-induced hypertension (such as long-term use of glucocorticoids, contraceptives, estrogens, herbs containing glycyrrhizin), pregnancy hypertension and other secondary hypertension;
• • Hereditary diseases: such as false aldosteronism (Liddle syndrome), Bartter syndrome, familial hypokalemia and hypomagnesemia (Gitelman syndrome);
• • Cerebral apoplexy, myocardial infarction and stent implantation occurred in the past 3 months;
• • Serious other basic, such as heart dysfunction (grade IV), acute infection, autoimmune diseases, various malignant tumors and so on;
• • Participated in other clinical trials within the past 3 months;
• • Individual pregnancy, nursing or planning pregnancy;